Duke Human Vaccine Institute

Homegrown Immunotherapy Trialed in Lung Cancer

A decade since it’s discovery in the Patz Lab, a first-in-class, novel targeted immunotherapy developed at DCI, is now in a phase 1b clinical trial.

December 14, 2020

DCI Research Features

Patz’s Human-Derived Antibody Treatment Moves Forward

Patz's Human-Derived Antibody Treatment Moves Forward With Boost from NCI and Manufacturing Agreement Grid Therapeutics, LLC, a new start-up company l...

October 31, 2017

DCI Research Announcements